(Q33511263)

27 July 2017

title

The role of salvage reirradiation for malignant gliomas that progress on bevacizumab (English)

1 reference

27 July 2017

1 reference

Rajan Jain

8

0 references

Tom Mikkelsen

11

object named as

Tom Mikkelsen

1 reference

27 July 2017

Roy G Torcuator

1

1 reference

27 July 2017

Ravneet Thind

2

1 reference

27 July 2017

Mehul Patel

3

1 reference

27 July 2017

Y S Mohan

4

1 reference

27 July 2017

Joseph Anderson

5

1 reference

27 July 2017

Thomas Doyle

6

1 reference

27 July 2017

Samuel Ryu

7

1 reference

27 July 2017

Lonni Schultz

9

1 reference

27 July 2017

Mark Rosenblum

10

1 reference

27 July 2017

publication date

17 October 2009

1 reference

Journal of Neuro-Oncology

27 July 2017

published in

1 reference

27 July 2017

volume

97

1 reference

27 July 2017

issue

3

1 reference

27 July 2017

page(s)

401-407

1 reference

https://scigraph.springernature.com/pub.10.1007/s11060-009-0034-y

27 July 2017

exact match

0 references

cites work

Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11060-009-0034-Y

Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11060-009-0034-Y

Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11060-009-0034-Y

Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution.

21 January 2018

1 reference

12 December 2020

Retardation of tumor growth in mice caused by radiation-induced injury of tumor bed stroma: dependency on tumor type

1 reference

12 December 2020

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab

1 reference

12 December 2020

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

1 reference

12 December 2020

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

1 reference

12 December 2020

Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells

1 reference

12 December 2020

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

12 December 2020

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

1 reference

12 December 2020

Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.

1 reference

12 December 2020

Dosimetric study using different leaf-width MLCs for treatment planning of dynamic conformal arcs and intensity-modulated radiosurgery

1 reference

12 December 2020

2D/3D image fusion for accurate target localization and evaluation of a mask based stereotactic system in fractionated stereotactic radiotherapy of cranial lesions.

1 reference

12 December 2020

Salvage reirradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival.

1 reference

12 December 2020

10.1007/S11060-009-0034-Y

Identifiers

DOI

1 reference

Dimensions Publication ID

27 July 2017

1023277883

0 references

1 reference